The phase 3 NRG GU-005 trial did not show a DFS benefit for SBRT vs IMRT in intermediate-risk prostate cancer, but SBRT decreased rectal toxicity. Stereotactic body radiation therapy (SBRT) preserves ...
SAN FRANCISCO, September 29, 2025 — For patients with intermediate-risk, localized prostate cancer, radiation therapy delivered in five sessions reduced patient-reported side effects compared to ...
Results of the NRG Oncology NRG-GU005 clinical study comparing stereotactic body radiation therapy (SBRT) to moderately hypofractionated intensity-modulated radiation therapy (MH-IMRT) for patients ...
For patients with intermediate-risk, localized prostate cancer, radiation therapy delivered in five sessions reduced patient-reported side effects compared to longer courses of radiation, according to ...
Short-term androgen deprivation combined with high-dose radiation therapy aids oncologic control in localized prostate cancer. In patients with intermediate- or high-risk localized prostate cancer, ...
A study led by UCLA Health Jonsson Comprehensive Cancer Center investigators found that stereotactic body radiotherapy (SBRT), a form of high-dose radiation delivered in just five sessions, after ...
It used to be that radiation therapy for prostate cancer involved weeks or months of repeat visits to a clinic for treatment. Today that's not necessarily true. Instead of giving small doses (called ...
Prostatectomy and radiation therapy show no survival difference for low-risk prostate cancer, but higher-risk cases require careful treatment consideration. The ProtecT trial supports active ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results